In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Viagra "Wild Thing" Ads Too Wild For FDA; Pfizer Will Pull Them

This article was originally published in The Pink Sheet Daily

  • News
  • Tericke Blanchard

Executive Summary

FDA declares that the ads, featuring a man with blue horns, cross the line and cannot be considered unbranded "reminder" ads. Pfizer says it will discuss FDA's concerns before deciding whether and how to resume the campaign.

You may also be interested in...



Nonprofit To Subpoena Pfizer Documents Related To Viagra Online Distribution

Subpoena is part of the discovery process in a lawsuit in which the AIDS Healthcare Foundation alleges improper Viagra marketing practices.

Nonprofit To Subpoena Pfizer Documents Related To Viagra Online Distribution

Subpoena is part of the discovery process in a lawsuit in which the AIDS Healthcare Foundation alleges improper Viagra marketing practices.

Ball Drops On Pfizer's New Year's Eve-Themed Ads For Viagra

AIDS Healthcare Foundation urges Pfizer to curb "irresponsible" advertising for its erectile dysfunction drug.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

PS058135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By